Award Notice
SUPPLY of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)
Dept of Defense · Defense Health Agency (DHA) · Sol. 12481254
No deadlineSole sourceClosed
The agency plans to award to one named company. Others can only submit a capability statement to challenge it.
This contract has been awarded
Awarded to Novartis Pharmaceuticals Corporation for $480K on Sep 30, 2026.
Recent DHA contract awards: who won →
Search open federal contracts for similar work.
AI summary Beta
No AI summary for this notice yet.
Save it to generate your own AI brief in its bid workspace: a plain-English summary, the red flags, and how well your business fits.
Key facts
- Posted
- Oct 8, 2026
- Notice type
- Award Notice
- Solicitation
- 12481254
- Agency
- Dept of Defense · Defense Health Agency (DHA)
- Office
- Defense Health Agency
- Place of performance
- Bethesda, MD, 20889
Before you respond
Full notice text from SAM.gov
Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to award a contract directly to Novartis. This approach is deemed to be in the government's best interest to ensure the seamless delivery of these critical supplies and maintain continuity of patient care at WRNMMC. The acquisition will be treated as a sole-source procurement.